Drug
Reproxalap clinical trials
- studies test it
- 20
- open now
- 1
- in phase 3
- 11
- first study started
- 2016
Keep track of what changes. Save the reproxalap studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 0
Aldeyra Therapeutics, Inc. (19) · Aldena Therapeutics (1)
Studies
Open first, then newest update. How each study uses reproxalap is read from its arms, and is right about nine times in ten.
Testing it · 20
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia AreataRecruitingPhase 1/2Aldena TherapeuticsNCT06826196Written as ALD-102 Solution
- The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisCompletedPhase 3Aldeyra Therapeutics, Inc.NCT05234554Written as Reproxalap Ophthalmic Solution (0.25%)
- A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseCompletedPhase 3Aldeyra Therapeutics, Inc.NCT06493604Written as Reproxalap Ophthalmic Solution (0.25%)
- A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedPhase 3Aldeyra Therapeutics, Inc.NCT04735393Written as Reproxalap Ophthalmic Solution (0.25%)
- A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseCompletedPhase 3Aldeyra Therapeutics, Inc.NCT06424444Written as Reproxalap ophthalmic solution (0.25%)
- A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseCompletedPhase 3Aldeyra Therapeutics, Inc.NCT06389214Written as Reproxalap Ophthalmic Solution (0.25%)
- A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic ConjunctivitisCompletedPhase 1/2Aldeyra Therapeutics, Inc.NCT03660878Written as Reproxalap Ophthalmic Solution (0.25%)
- The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseCompletedPhase 2/3Aldeyra Therapeutics, Inc.NCT04674358Written as Reproxalap Ophthalmic Solution (0.25%)
- The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseCompletedPhase 3Aldeyra Therapeutics, Inc.NCT05062330Written as Reproxalap Ophthalmic Solution (0.25%)
- An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberCompletedPhase 2Aldeyra Therapeutics, Inc.NCT05102409Written as Reproxalap Ophthalmic Solution (0.25%)
- A Clinical Trial to Assess Subjects With Dry Eye Disease.CompletedPhase 2Aldeyra Therapeutics, Inc.NCT04971031Written as Reproxalap Ophthalmic Solution (0.25%)
- A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure ChamberCompletedPhase 1/2Aldeyra Therapeutics, Inc.NCT03709121Written as Reproxalap Ophthalmic Solution (0.25%)
- ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisCompletedPhase 3Aldeyra Therapeutics, Inc.NCT03494504Written as Reproxalap Ophthalmic Solution (0.25%)
- SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.CompletedPhase 3Aldeyra Therapeutics, Inc.NCT03131154Written as ADX-102 Ophthalmic Solution (0.5%)
- A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedPhase 2Aldeyra Therapeutics, Inc.NCT03404115Written as Reproxalap Ophthalmic Solution (0.25%)
- A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeCompletedPhase 2Aldeyra Therapeutics, Inc.NCT03162783Written as ADX-102 Ophthalmic Solution (0.5%)
- A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseCompletedPhase 2Aldeyra Therapeutics, Inc.NCT05424549Written as Reproxalap Ophthalmic Solution (0.25%)
- The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.CompletedPhase 3Aldeyra Therapeutics, Inc.NCT04207736Written as Reproxalap Ophthalmic Solution (0.25%)
- RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)CompletedPhase 3Aldeyra Therapeutics, Inc.NCT03445650Written as ADX-102 1% Topical Dermal Cream (reproxalap)
- A Study of ADX-102 in Subjects With Allergic ConjunctivitisCompletedPhase 2Aldeyra Therapeutics, Inc.NCT03012165Written as ADX-102 Ophthalmic Drops (0.5%)
Codes
What other systems call reproxalap · ClinicalTrials.gg INT001609
- MeSH (NLM) C000716728reproxalapOne source NLM
- UNII (FDA) F0GIZ22IJHREPROXALAPConfirmed FDA, NLM
- NCI Thesaurus C152196ReproxalapOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716728 | reproxalap | One source NLM |
| UNII (FDA) | F0GIZ22IJH | REPROXALAP | Confirmed FDA, NLM |
| NCI Thesaurus | C152196 | Reproxalap | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.